title: Reversible, enzyme-activated monoamine oxidase inhibitors: new advances.
authors.affiliation: Pharmaceutical Research Dept., F. Hoffmann-La Roche & Co. Ltd., Basle, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Da Prada
authors.forename: R
authors.initials: R
authors.lastname: Kettler
authors.forename: A M
authors.initials: AM
authors.lastname: Cesura
authors.forename: J G
authors.initials: JG
authors.lastname: Richards
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D003010:Clorgyline / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010624:Phenelzine / Q000494:pharmacology; D010848:Picolinic Acids / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D012642:Selegiline / Q000494:pharmacology
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010848:Picolinic Acids; D010880:Piperidines; D012642:Selegiline; C059303:lazabemide; C038213:brofaromine; D003010:Clorgyline; D010624:Phenelzine; D020912:Moclobemide